Switching From Dual Antiplatelet Therapy to Monotherapy With Potent P2Y12 Inhibitors

Description

Ticagrelor currently represents the most tested and commonly used P2Y12 inhibitor monotherapy following percutaneous coronary intervention. The purpose of this study is to conduct a head-to-head comparison on the pharmacodynamic efficacy of ticagrelor-based and prasugrel-based single antiplatelet therapy. To determine if the PD profiles of ticagrelor- and prasugrel-based SAPT are comparable, we aim to conduct a non-inferiority study between the two strategies.

Conditions

Coronary Artery Disease

Talk to us

Study Overview

On this page

Study Details

Study overview

Ticagrelor currently represents the most tested and commonly used P2Y12 inhibitor monotherapy following percutaneous coronary intervention. The purpose of this study is to conduct a head-to-head comparison on the pharmacodynamic efficacy of ticagrelor-based and prasugrel-based single antiplatelet therapy. To determine if the PD profiles of ticagrelor- and prasugrel-based SAPT are comparable, we aim to conduct a non-inferiority study between the two strategies.

Switching From Dual Antiplatelet Therapy to Monotherapy With Potent P2Y12 Inhibitors: Pharmadodynamic Comparison Between Prasugrel and Ticagrelor Monotherapy. The Switching Antiplatelet -7 (SWAP-7) Study

Switching From Dual Antiplatelet Therapy to Monotherapy With Potent P2Y12 Inhibitors

Condition
Coronary Artery Disease
Intervention / Treatment

-

Contacts and Locations

Jacksonville

University of Florida Jacksonville, Jacksonville, Florida, United States, 32209

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Patients on DAPT with aspirin plus prasugrel 10 mg or ticagrelor 90 mg bid as per standard of care at least 90 days after PCI.
  • 2. Age between 18 and 75 years old
  • 3. Able to provide written informed consent
  • 1. Prior history of stent thrombosis
  • 2. PCI within 90 days.
  • 3. History of stroke/TIA
  • 4. Age \> 75 years old
  • 5. Weight \< 60 kg
  • 6. History of intracranial hemorrhage
  • 7. On treatment with any oral anticoagulant or chronic low-molecular-weight heparin (at venous thrombosis treatment, not for prophylaxis)
  • 8. Patients with known coagulation disorders
  • 9. Known severe hepatic impairment
  • 10. Hypersensitivity to prasugrel or ticagrelor
  • 11. Pregnant and breastfeeding persons \[persons of childbearing age must use reliable birth control (i.e., oral contraceptives) while participating in the study\]. If the potential subject is a person of childbearing potential, a pregnancy test will be done. If the subject is pregnant, participation in this study will end.

Ages Eligible for Study

18 Years to 75 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Florida,

Francesco Franchi, MD, PRINCIPAL_INVESTIGATOR, University of Florida College of Medicine Jacksonville

Study Record Dates

2026-12-31